“GAO reviewed the Department of Health and Human Services, Centers for Medicare & Medicaid Services’ (CMS) new rule entitled “Medicare Program; Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs; Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency; Additional Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency.” GAO found that the final rule (1) revises the Medicare Advantage program and Medicare Prescription Drug Benefit program regulations to implement changes related to marketing and communications, past performance, Star Ratings, network adequacy, medical loss ratio reporting, special requirements during disasters or public emergencies, and pharmacy price concessions; (2) revises regulations related to dual eligible special needs plans, other special needs plans, and cost contract plans; and (3) finalizes certain Star Ratings provisions that were included in two prior interim final rules.”
“Enclosed is our assessment of CMS’s compliance with the procedural steps required by section 801(a)(1)(B)(i) through (iv) of title 5 with respect to the rule…”
Access the full 4-page report here.
Source: Department of Health and Human Services, Centers for Medicare & Medicaid Services: Medicare Program; Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs; Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency; Additional Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency – May 19, 2022. GAO.
